15
Views
69
CrossRef citations to date
0
Altmetric
Original Article

Cellular Uptake of Misonidazole and Analogues with Acidic or Basic Functions

, , &
Pages 629-643 | Received 05 Oct 1984, Accepted 21 Dec 1984, Published online: 03 Jul 2009
 

Summary

Average intracellular concentrations of five radiosensitizers in hamster fibroblast-like V79-379A cells in vitro were measured by high performance liquid chromatography, varying the extracellular pH (pHe) and estimating the apparent intracellular pH from the distribution of 5,5-dimethyloxazolidine-2,4-dione. The intracellular: extracellular concentration ratio for the 2-nitroimidazole, misonidazole was constant at about 0·7 for pHe = 6·6–7·6, whereas the weak base, Ro 03-8799 (1-(2-nitro-1-imidazolyl)-3-N-piperidino-2-propanol) was concentrated intracellularly at pHe = 7·3–7·4 by a factor of 3·3, the factor increasing from about 0·8 at pHe = 6·0, to 7·5 at pHe = 7·85. The weak acid, azomycin (2-nitroimidazole) showed approximately constant uptake (factor 1·1) between pHe = 6·0–7·0, decreasing to 0·8 at pHe = 7·3 and 0·4 at pHe = 7·8. Measurements of intracellular uptake of Ro 31-0052 (the more hydrophilic and less basic 3′-hydroxypiperidino analogue of Ro 03-8799) and of Ro 31-0258 (3-(2-nitro-1-imidazolyl)propionic acid, a stronger acid than azomycin) were made for comparison. The results were compared with theoretical calculations of pH-induced concentration gradients; the time dependence of the uptake of the bases is not at present clearly understood. These measurements of uptake are broadly consistent with the distribution of misonidazole and Ro 03-8799 in human and animal tissues and provide a useful insight into the likely intracellular concentrations in the clinical use of Ro 03-8799 or other basic radiosensitizers. The measurements also resolve the apparent discrepancy in radiosensitizer efficiency for weak bases in vitro and in vivo which has been previously noted.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.